Literature DB >> 17465216

EGFR and VEGFR2 protein expressions in bone metastases of clear cell renal cancer.

Gayane Badalian1, Katalin Derecskei, Attila Szendroi, Miklós Szendroi, József Tímár.   

Abstract

BACKGROUND: EGFR and VEGFR2 protein expressions are hallmarks of clear cell renal cancer (RCC) with questionable prognostic impact. The skeletal system is one of the most common metastatic sites of RCC. Unfortunately, there are no data for EGFR and VEGFR2 protein expression in such lesions.
MATERIALS AND METHODS: Twenty cases of bone metastatic clear cell RCC were analyzed. EGFR and VEGFR2 proteins were detected by immunohistochemistry and analyzed by morphometry scoring both % positivity and the intensity.
RESULTS: EGFR protein scores were significantly reduced in bone metastases of RCC due to the reduction of EGFR protein expression in about one third of the cases (7/20). The VEGFR2 protein-positive phenotype of clear cell RCC was relatively frequent (7/20, 35%), but was lost in bone metastases (2/20, 10%).
CONCLUSION: These data suggest a phenotypic/genotypic change of clear cell RCC during the progression to bones and warrant further investigation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17465216

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  9 in total

Review 1.  Vascular endothelial growth factor receptor-2 in breast cancer.

Authors:  Shanchun Guo; Laronna S Colbert; Miles Fuller; Yuanyuan Zhang; Ruben R Gonzalez-Perez
Journal:  Biochim Biophys Acta       Date:  2010-05-11

2.  Renal cell carcinoma bone metastases: clinical advances.

Authors:  Chakshu Sahi; Jennifer J Knox; Mark Clemons; Anthony M Joshua; Reuben Broom
Journal:  Ther Adv Med Oncol       Date:  2010-03       Impact factor: 8.168

3.  Tumor biology of non-metastatic stages of clear cell renal cell carcinoma; overexpression of stearoyl desaturase-1, EPO/EPO-R system and hypoxia-related proteins.

Authors:  Tania Romina Stoyanoff; Juan Pablo Rodríguez; Juan Santiago Todaro; Joaquín Diego Espada; Juan Pablo Melana Colavita; Nora Cristina Brandan; Adriana Mónica Torres; María Victoria Aguirre
Journal:  Tumour Biol       Date:  2016-07-28

Review 4.  The future of tyrosine kinase inhibitors: single agent or combination?

Authors:  Keith T Flaherty
Journal:  Curr Oncol Rep       Date:  2008-05       Impact factor: 5.075

Review 5.  VEGF targets the tumour cell.

Authors:  Hira Lal Goel; Arthur M Mercurio
Journal:  Nat Rev Cancer       Date:  2013-12       Impact factor: 60.716

Review 6.  Personalized medicine in hematology - A landmark from bench to bed.

Authors:  Gayane Badalian-Very
Journal:  Comput Struct Biotechnol J       Date:  2014-08-08       Impact factor: 7.271

7.  Effect of Targeted Therapy With Pazopanib on Expression Levels of Transcription, Growth Factors and Components of AKT/m-TOR Signaling Pathway in Patients with Renal Cell Carcinoma

Authors:  Liudmila V Spirina; Evgeny A Usynin; Zahar A Yurmazov; Elena M Slonimskaya; Irina V Kondakova
Journal:  Asian Pac J Cancer Prev       Date:  2017-11-26

8.  Complete remission of metastatic renal cell carcinoma to the bone with sunitinib.

Authors:  Akihiro Yoshimura; Wataru Nakata; Gaku Yamamichi; Go Tsujimura; Yuichi Tsujimoto; Mikio Nin; Masao Tsujihata
Journal:  Urol Case Rep       Date:  2020-04-17

9.  Molecular design, synthesis and in vitro biological evaluation of thienopyrimidine-hydroxamic acids as chimeric kinase HDAC inhibitors: a challenging approach to combat cancer.

Authors:  Mona M Abdel-Atty; Nahla A Farag; Rabah A T Serya; Khaled A M Abouzid; Samar Mowafy
Journal:  J Enzyme Inhib Med Chem       Date:  2021-12       Impact factor: 5.051

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.